We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B Turnover 46.34%
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
-17.92%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$999M
AUM Growth
-$111M
Cap. Flow
+$145M
Cap. Flow %
14.51%
Top 10 Hldgs %
53.54%
Holding
68
New
18
Increased
13
Reduced
17
Closed
15
Avg Time Held Equity + Options
0.6 years
Top 10 Avg Time Held Equity + Options
1.3 years
Top 20 Avg Time Held Equity + Options
0.9 years
Avg Time Held Equity only
0.6 years
Top 10 Avg Time Held Equity only
1.4 years
Top 20 Avg Time Held Equity only
0.9 years

Top Buys

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$73.3M
2
XNCR icon
Xencor
XNCR
+$36.3M
3
IONS icon
Ionis Pharmaceuticals
IONS
+$33.3M
4
SLDB icon
Solid Biosciences
SLDB
+$27.2M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$25.8M

Top Sells

Rank Stock Value
1
MGNX icon
MacroGenics
MGNX
+$31.8M
2
ASND icon
Ascendis Pharma A/S
ASND
+$25.6M
3
KYNB icon
Kyntra Bio
KYNB
+$22.2M
4
SRRK icon
Scholar Rock
SRRK
+$20.2M
5
RARE icon
Ultragenyx Pharmaceutical
RARE
+$19.4M

Sector Composition

Rank Sector Weight
1 Healthcare 86.99%
2 Miscellaneous 13.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
CELG
26
CALL
DELISTED
Celgene Corp
CELG
$12.5M 1.25%
195,000
-5,000
-3% -$369K
2017 Q4
4 quarters
IRWD icon
27
CALL
Ironwood Pharmaceuticals
IRWD
$623M
$12.1M 1.22%
1,399,726
+722,012
+107% +$8.29M
2017 Q3
5 quarters
MYOK
28
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$11.5M 1.15%
+234,381
New +$12.9M
2018 Q4
0 quarters
RYTM icon
29
Rhythm Pharmaceuticals
RYTM
$6.06B
$10.8M 1.08%
+400,838
New +$11.1M
2018 Q4
0 quarters
NKTR icon
30
CALL
Nektar Therapeutics
NKTR
$1.29B
$10.4M 1.04%
21,113
-554
-3% -$334K
2018 Q3
1 quarter
WVE icon
31
Wave Life Sciences
WVE
$629M
$9.84M 0.98%
233,933
+189,092
+422% +$8.41M
2017 Q3
5 quarters
SURF
32
DELISTED
Surface Oncology, Inc. Common Stock
SURF
$9.59M 0.96%
2,261,328
+897,849
+66% +$6.93M
2018 Q2
2 quarters
RUBY
33
DELISTED
Rubius Therapeutics, Inc
RUBY
$9.52M 0.95%
592,128
– –
2018 Q3
1 quarter
ARRY icon
34
DELISTED
Array Biopharma Inc
ARRY
$9.18M 0.92%
+644,002
New +$9.77M
2018 Q4
0 quarters
PRTA icon
35
Prothena Corp
PRTA
$436M
$8.63M 0.86%
+838,219
New +$9.96M
2018 Q4
0 quarters
DNTH icon
36
Dianthus Therapeutics
DNTH
$4.17B
$7.86M 0.79%
86,218
-9,913
-10% -$1.35M
2018 Q2
2 quarters
IMDZ
37
DELISTED
Immune Design Corp.
IMDZ
$7.28M 0.73%
5,603,191
+3,361,291
+150% +$5.84M
2017 Q4
4 quarters
RCKT icon
38
Rocket Pharmaceuticals
RCKT
$259M
$6.67M 0.67%
+450,000
New +$7.47M
2018 Q4
0 quarters
CRSP icon
39
CRISPR Therapeutics
CRSP
$4.98B
$5.97M 0.6%
208,850
-291,150
-58% -$10.1M
2018 Q3
1 quarter
NGNE icon
40
Neurogene
NGNE
$479M
$4.89M 0.49%
113,294
– –
2018 Q2
2 quarters
PTLA
41
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$4.84M 0.48%
+247,858
New +$5.1M
2018 Q4
0 quarters
ACRS icon
42
Aclaris Therapeutics
ACRS
$514M
$4.54M 0.45%
+613,728
New +$6.33M
2018 Q4
0 quarters
FPRX
43
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$3.04M 0.3%
+326,775
New +$3.89M
2018 Q4
0 quarters
CORT icon
44
Corcept Therapeutics
CORT
$12.3B
$2.22M 0.22%
+166,005
New +$2.19M
2018 Q4
0 quarters
CRIS icon
45
Curis
CRIS
$1.23M
$2.06M 0.21%
+7,456
New +$4.08M
2018 Q4
0 quarters
DVAX icon
46
DELISTED
Dynavax Technologies
DVAX
$1.28M 0.13%
+140,118
New +$1.55M
2018 Q4
0 quarters
CHMA
47
DELISTED
Chiasma, Inc. Common Stock
CHMA
$1.18M 0.12%
379,753
– –
2018 Q3
1 quarter
CRVS icon
48
Corvus Pharmaceuticals
CRVS
$829M
$1.08M 0.11%
295,420
-55,981
-16% -$382K
2017 Q2
6 quarters
TRAW icon
49
Traws Pharma
TRAW
$6.19M
$893K 0.09%
1,129
-204
-15% -$348K
2018 Q2
2 quarters
ARVN icon
50
Arvinas
ARVN
$468M
$643K 0.06%
50,000
– –
2018 Q3
1 quarter
1
2
3

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q4 2018 Portfolio in Review

As of Q4 2018, EcoR1 Capital held 68 positions worth $999M, down 10% from $1.11B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

EcoR1 Capital deployed $145M of net new capital in Q4 2018, opening 18 new positions and adding to 13 existing holdings. Its largest new stake was argenx: 825,087 shares worth $79.3M.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, down from 87% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Ascendis Pharma A/S, an estimated $25.6M trimmed.

  • EcoR1 Capital's largest Q4 2018 buy was argenx: 825,087 shares worth $79.3M.
  • EcoR1 Capital added most to Ionis Pharmaceuticals in Q4 2018, an estimated $33.3M increase.
  • EcoR1 Capital's biggest Q4 2018 reduction was Ascendis Pharma A/S, cutting an estimated $25.6M.
  • EcoR1 Capital fully exited MacroGenics in Q4 2018, selling an estimated $31.8M.
  • EcoR1 Capital's ten largest holdings make up 54% of its $999M portfolio in Q4 2018.
  • EcoR1 Capital opened 18 new positions and closed 15 in Q4 2018.
  • EcoR1 Capital's portfolio value fell 10% quarter-over-quarter to $999M.

Based on EcoR1 Capital's 13F filing for Q4 2018, filed 14 Feb 2019.